Paul C Hendrie
Overview
Explore the profile of Paul C Hendrie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Martin D, Silas S, Covner A, Hendrie P, Stewart F
J Natl Compr Canc Netw
. 2015 Apr;
13(4):435-40.
PMID: 25870380
Conversion to the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) was mandated for October 1, 2014, but was delayed by one year. ICD-10 accommodates newly developed diagnoses and...
32.
Shadman M, Mawad R, Dean C, Chen T, Shannon-Dorcy K, Sandhu V, et al.
Am J Hematol
. 2015 Feb;
90(6):483-6.
PMID: 25689471
Previous studies suggest that idarubicin/cytarabine(ara-C)/pravastatin (IAP) is an active salvage regimen for patients with AML. We therefore investigated this regimen in patients with newly-diagnosed AML or MDS (≥10% blasts). Patients...
33.
Becker P, Medeiros B, Stein A, Othus M, Appelbaum F, Forman S, et al.
Am J Hematol
. 2014 Dec;
90(4):295-300.
PMID: 25545153
Prior study of the combination of clofarabine and high dose cytarabine with granulocyte colony-stimulating factor (G-CSF) priming (GCLAC) in relapsed or refractory acute myeloid leukemia resulted in a 46% rate...
34.
Tong W, Sandhu V, Wood B, Hendrie P, Becker P, Pagel J, et al.
Haematologica
. 2014 Dec;
100(3):e97-8.
PMID: 25527567
No abstract available.
35.
Lionberger J, Pagel J, Sandhu V, Xie H, Shadman M, Mawad R, et al.
Br J Haematol
. 2014 Apr;
166(3):375-81.
PMID: 24749757
Combinations of agents may improve outcomes among elderly acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) patients. We performed an adaptive phase I/II trial for newly-diagnosed AML or high-risk...
36.
Hendrie P, Garcia D
J Natl Compr Canc Netw
. 2013 Nov;
11(11):1446-9.
PMID: 24225975
Patients with cancer have long been an important and enigmatic part of basic science and clinical research in thromboembolic disease. The reciprocal deleterious effects on outcomes of a cancer diagnosis...
37.
Walter R, Medeiros B, Gardner K, Orlowski K, Gallegos L, Scott B, et al.
Haematologica
. 2013 Oct;
99(1):54-9.
PMID: 24142996
Epigenetic therapeutics such as the histone deacetylase inhibitor, vorinostat, and the DNA methyltransferase I inhibitor, azacitidine, enhance gemtuzumab ozogamicin efficacy in vitro. We therefore investigated vorinostat/azacitidine/gemtuzumab ozogamicin in 52 adults...
38.
Ostronoff F, Othus M, Kantarjian H, Meshinchi S, Ravandi F, Hendrie P, et al.
Br J Haematol
. 2013 Jul;
163(1):130-2.
PMID: 23829510
No abstract available.
39.
Becker P, Kantarjian H, Appelbaum F, Petersdorf S, Storer B, Pierce S, et al.
Br J Haematol
. 2011 Aug;
155(2):182-9.
PMID: 21848522
This phase I/II study was conducted to determine the maximum tolerated dose, toxicity, and efficacy of clofarabine in combination with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming (GCLAC),...
40.
Hu J, Renaud G, Gomes T, Golmes T, Ferris A, Hendrie P, et al.
Mol Ther
. 2008 Jun;
16(9):1617-23.
PMID: 18578011
Insertional mutagenesis continues to be a major concern in hematopoietic stem-cell gene therapy. Nonconventional gene transfer vectors with more favorable integration features in comparison with conventional retrovirus and lentivirus vectors...